Cargando…
Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics
BACKGROUND: In asthma, exacerbations and poor disease control are linked to airway allergic inflammation. Serum periostin has been proposed as a systemic biomarker of eosinophilic inflammation. This pilot study aims at evaluating whether in patients with moderate asthma, higher baseline levels of se...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142433/ https://www.ncbi.nlm.nih.gov/pubmed/27965769 http://dx.doi.org/10.1186/s40733-015-0019-x |
_version_ | 1782472775692189696 |
---|---|
author | Scichilone, N. Crimi, C. Benfante, A. Battaglia, S. Iemmolo, M. Spatafora, M. Crimi, N. |
author_facet | Scichilone, N. Crimi, C. Benfante, A. Battaglia, S. Iemmolo, M. Spatafora, M. Crimi, N. |
author_sort | Scichilone, N. |
collection | PubMed |
description | BACKGROUND: In asthma, exacerbations and poor disease control are linked to airway allergic inflammation. Serum periostin has been proposed as a systemic biomarker of eosinophilic inflammation. This pilot study aims at evaluating whether in patients with moderate asthma, higher baseline levels of serum periostin are associated with a greater risk of exacerbation. METHODS: Fifteen outpatients with moderate allergic asthma were recruited. Serum concentrations of periostin were assessed (ELISA) at baseline, and the frequency of asthma exacerbations was recorded during a one-year follow-up. RESULTS: Patients (M/F: 10/5, mean age of 47.6 ± 11.0 years) had mean ACQ score of 5.5 ± 4.2 and FEV(1)%pred of 81.9 ± 21.7 %. Baseline serum levels of periostin did not correlate with lung function parameters, nor with the ACQ score (p ≥0.05 for all analyses). Five subjects (33 % of the study group) reported one or more exacerbations during the following year. Baseline serum levels of periostin were significantly higher in subjects who experienced one or more exacerbations during the one year period of follow-up, compared with subjects with no exacerbations: median serum periostin level was 4047 ng/ml (range: 2231 to 4889 ng/ml) and 222 ng/ml (range 28.2 to 1631 ng/ml) respectively; p = 0.001. CONCLUSION: The findings of the present pilot study could form the basis for the design of larger studies aiming at developing strategies to identify asthmatic patients at risk for exacerbations. |
format | Online Article Text |
id | pubmed-5142433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-51424332016-12-13 Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics Scichilone, N. Crimi, C. Benfante, A. Battaglia, S. Iemmolo, M. Spatafora, M. Crimi, N. Asthma Res Pract Research BACKGROUND: In asthma, exacerbations and poor disease control are linked to airway allergic inflammation. Serum periostin has been proposed as a systemic biomarker of eosinophilic inflammation. This pilot study aims at evaluating whether in patients with moderate asthma, higher baseline levels of serum periostin are associated with a greater risk of exacerbation. METHODS: Fifteen outpatients with moderate allergic asthma were recruited. Serum concentrations of periostin were assessed (ELISA) at baseline, and the frequency of asthma exacerbations was recorded during a one-year follow-up. RESULTS: Patients (M/F: 10/5, mean age of 47.6 ± 11.0 years) had mean ACQ score of 5.5 ± 4.2 and FEV(1)%pred of 81.9 ± 21.7 %. Baseline serum levels of periostin did not correlate with lung function parameters, nor with the ACQ score (p ≥0.05 for all analyses). Five subjects (33 % of the study group) reported one or more exacerbations during the following year. Baseline serum levels of periostin were significantly higher in subjects who experienced one or more exacerbations during the one year period of follow-up, compared with subjects with no exacerbations: median serum periostin level was 4047 ng/ml (range: 2231 to 4889 ng/ml) and 222 ng/ml (range 28.2 to 1631 ng/ml) respectively; p = 0.001. CONCLUSION: The findings of the present pilot study could form the basis for the design of larger studies aiming at developing strategies to identify asthmatic patients at risk for exacerbations. BioMed Central 2016-01-04 /pmc/articles/PMC5142433/ /pubmed/27965769 http://dx.doi.org/10.1186/s40733-015-0019-x Text en © Scichilone et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Scichilone, N. Crimi, C. Benfante, A. Battaglia, S. Iemmolo, M. Spatafora, M. Crimi, N. Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics |
title | Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics |
title_full | Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics |
title_fullStr | Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics |
title_full_unstemmed | Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics |
title_short | Higher serum levels of periostin and the risk of exacerbations in moderate asthmatics |
title_sort | higher serum levels of periostin and the risk of exacerbations in moderate asthmatics |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5142433/ https://www.ncbi.nlm.nih.gov/pubmed/27965769 http://dx.doi.org/10.1186/s40733-015-0019-x |
work_keys_str_mv | AT scichilonen higherserumlevelsofperiostinandtheriskofexacerbationsinmoderateasthmatics AT crimic higherserumlevelsofperiostinandtheriskofexacerbationsinmoderateasthmatics AT benfantea higherserumlevelsofperiostinandtheriskofexacerbationsinmoderateasthmatics AT battaglias higherserumlevelsofperiostinandtheriskofexacerbationsinmoderateasthmatics AT iemmolom higherserumlevelsofperiostinandtheriskofexacerbationsinmoderateasthmatics AT spataforam higherserumlevelsofperiostinandtheriskofexacerbationsinmoderateasthmatics AT crimin higherserumlevelsofperiostinandtheriskofexacerbationsinmoderateasthmatics |